Literature DB >> 32005651

Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people.

Gunnar Juliusson1, Martin Höglund2, Sören Lehmann2,3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32005651      PMCID： PMC7012470          DOI： 10.3324/haematol.2019.238857

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  25 in total

1.  Survival for older patients with acute myeloid leukemia: a population-based study.

Authors:  Betul Oran; Daniel J Weisdorf
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia.

Authors:  J W Yates; H J Wallace; R R Ellison; J F Holland
Journal:  Cancer Chemother Rep       Date:  1973 Nov-Dec

Review 3.  Azacitidine in adult patients with acute myeloid leukemia.

Authors:  Andre C Schuh; Hartmut Döhner; Lisa Pleyer; John F Seymour; Pierre Fenaux; Hervé Dombret
Journal:  Crit Rev Oncol Hematol       Date:  2017-06-03       Impact factor: 6.312

4.  Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.

Authors:  Gunnar Juliusson; Oskar Hagberg; Vladimir Lj Lazarevic; Emma Ölander; Petar Antunovic; Jörg Cammenga; Lovisa Wennström; Lars Möllgård; Mats Brune; Martin Jädersten; Stefan Deneberg; Sören Lehmann; Åsa Rangert Derolf; Martin Höglund
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

5.  Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.

Authors:  Gerwin Huls; Dana A Chitu; Violaine Havelange; Mojca Jongen-Lavrencic; Arjan A van de Loosdrecht; Bart J Biemond; Harm Sinnige; Beata Hodossy; Carlos Graux; Rien van Marwijk Kooy; Okke de Weerdt; Dimitri Breems; Saskia Klein; Jürgen Kuball; Dries Deeren; Wim Terpstra; Marie-Christiane Vekemans; Gert J Ossenkoppele; Edo Vellenga; Bob Löwenberg
Journal:  Blood       Date:  2019-01-10       Impact factor: 22.113

Review 6.  The World Health Organization (WHO) classification of the myeloid neoplasms.

Authors:  James W Vardiman; Nancy Lee Harris; Richard D Brunning
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

7.  Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Farhad Ravandi; Theresa Liu-Dumlao; Mark Brandt; Stefan Faderl; Sherry Pierce; Gautam Borthakur; Guillermo Garcia-Manero; Jorge Cortes; Hagop Kantarjian
Journal:  Blood       Date:  2012-10-15       Impact factor: 22.113

8.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Authors:  Gunnar Juliusson; Petar Antunovic; Asa Derolf; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Ulf Tidefelt; Anders Wahlin; Martin Höglund
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

9.  Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.

Authors:  Lisa Pleyer; Hartmut Döhner; Hervé Dombret; John F Seymour; Andre C Schuh; C L Beach; Arlene S Swern; Sonja Burgstaller; Reinhard Stauder; Michael Girschikofsky; Heinz Sill; Konstantin Schlick; Josef Thaler; Britta Halter; Sigrid Machherndl Spandl; Armin Zebisch; Angelika Pichler; Michael Pfeilstöcker; Eva M Autzinger; Alois Lang; Klaus Geissler; Daniela Voskova; Wolfgang R Sperr; Sabine Hojas; Inga M Rogulj; Johannes Andel; Richard Greil
Journal:  Int J Mol Sci       Date:  2017-02-15       Impact factor: 5.923

Review 10.  A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers.

Authors:  Jeannine Diesch; Anabel Zwick; Anne-Kathrin Garz; Anna Palau; Marcus Buschbeck; Katharina S Götze
Journal:  Clin Epigenetics       Date:  2016-06-21       Impact factor: 6.551
View more
  1 in total

Review 1.  Determination of fitness and therapeutic options in older patients with acute myeloid leukemia.

Authors:  Jorge E Cortes; Priyanka Mehta
Journal:  Am J Hematol       Date:  2021-01-12       Impact factor: 10.047
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.